 Organophosphorus Compounds
"Organophosphorus Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic compounds that contain phosphorus as an integral part of the molecule. Included under this heading is broad array of synthetic compounds that are used as PESTICIDES and DRUGS.
| Descriptor ID |
D009943
|
| MeSH Number(s) |
D02.705
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Organophosphorus Compounds".
Below are MeSH descriptors whose meaning is more specific than "Organophosphorus Compounds".
This graph shows the total number of publications written about "Organophosphorus Compounds" by people in this website by year, and whether "Organophosphorus Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 | | 1996 | 0 | 1 | 1 | | 1997 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 | | 1999 | 1 | 0 | 1 | | 2001 | 2 | 0 | 2 | | 2002 | 0 | 1 | 1 | | 2003 | 1 | 1 | 2 | | 2004 | 1 | 0 | 1 | | 2005 | 1 | 1 | 2 | | 2006 | 0 | 3 | 3 | | 2008 | 1 | 1 | 2 | | 2009 | 0 | 1 | 1 | | 2010 | 1 | 0 | 1 | | 2011 | 2 | 2 | 4 | | 2013 | 1 | 1 | 2 | | 2014 | 1 | 0 | 1 | | 2016 | 2 | 0 | 2 | | 2017 | 3 | 1 | 4 | | 2018 | 3 | 1 | 4 | | 2019 | 2 | 2 | 4 | | 2020 | 1 | 6 | 7 | | 2021 | 0 | 2 | 2 | | 2022 | 0 | 4 | 4 | | 2023 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Organophosphorus Compounds" by people in Profiles.
-
Paul S, Caruthers MH. Synthesis of Backbone-Modified Morpholino Oligonucleotides Using Phosphoramidite Chemistry. Molecules. 2023 Jul 13; 28(14).
-
Hu Q, Liao Y, Cao J, Fang B, Yun SY, Kinose F, Haura EB, Lawrence HR, Doebele RC, Koomen JM, Rix U. Differential Chemoproteomics Reveals MARK2/3 as Cell Migration-Relevant Targets of the ALK Inhibitor Brigatinib. Chembiochem. 2023 06 01; 24(11):e202200766.
-
Jahanzeb M, Lin HM, Wu Y, Zhang P, Gorritz M, McGuiness CB, Huang WT, Sun K, Chen CC, Camidge DR. Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States. Oncologist. 2022 09 02; 27(9):790-798.
-
Reckamp KL, Lin HM, Cranmer H, Wu Y, Zhang P, Kay S, Walton LJ, Shen J, Popat S, Camidge DR. Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L. Curr Med Res Opin. 2022 09; 38(9):1587-1593.
-
Reckamp KL, Lin HM, Cranmer H, Wu Y, Zhang P, Walton LJ, Kay S, Cichewicz A, Neupane B, Fahrbach K, Popat S, Camidge DR. Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer. Future Oncol. 2022 Jun; 18(20):2499-2510.
-
Gupta N, Reckamp KL, Camidge DR, Kleijn HJ, Ouerdani A, Bellanti F, Maringwa J, Hanley MJ, Wang S, Zhang P, Venkatakrishnan K. Population pharmacokinetic and exposure-response analyses from ALTA-1L: Model-based analyses supporting the brigatinib dose in ALK-positive NSCLC. Clin Transl Sci. 2022 05; 15(5):1143-1154.
-
Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, Garcia Campelo MR, Kim DW, Griesinger F, Felip E, Califano R, Spira AI, Gettinger SN, Tiseo M, Lin HM, Liu Y, Vranceanu F, Niu H, Zhang P, Popat S. Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. J Thorac Oncol. 2021 12; 16(12):2091-2108.
-
Garcia Campelo MR, Lin HM, Zhu Y, P?rol M, Jahanzeb M, Popat S, Zhang P, Camidge DR. Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK?+?non-small cell lung cancer (ALTA-1L). Lung Cancer. 2021 05; 155:68-77.
-
Ng TL, Johnson A, Nemenoff RA, Hsieh E, Osypuk AA, van Bokhoven A, Li H, Camidge DR, Schenk EL. Prospective Observational Study Revealing Early Pulmonary Function Changes Associated With Brigatinib Initiation. J Thorac Oncol. 2021 03; 16(3):486-491.
-
Aramjoo H, Farkhondeh T, Aschner M, Naseri K, Mehrpour O, Sadighara P, Roshanravan B, Samarghandian S. The association between diazinon exposure and dyslipidemia occurrence: a systematic and meta-analysis study. Environ Sci Pollut Res Int. 2021 Jan; 28(4):3994-4006.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|